Clinical Trial Update: Tofacitinib for Treatment of Moderate COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tofacitinib for moderate COVID-19 pneumonia has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Yale University | Conditions: COVID-19 Pneumonia | Phase 2 | Status: TERMINATED | Results posted: 2025-03-28